News and Press Releases

MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test

11 September 2024 -- Cambridge, UK -- MicrosensDx is excited to announce that it is working with The Mayr Group at Imperial College London to develop a novel biomarker test...

Category: Biotechnology, Other
Posted: September 11, 2024

204 Cambridge Science Park, Milton Road, Cambridge, CB4 0GZ

Closed Loop Medicine appoints Luba Greenwood as Chair of the Board of Directors

Appointment of notable investor and executive in healthcare and tech to support leadership team in preparation for commercial milestones 11 Sep 2024 -- London, UK -- Closed Loop Medicine Ltd.,...

Category: Biotechnology, Other, Pharmaceutical
Posted: September 11, 2024

Babraham Research Campus Cambridge CB22 3AT United Kingdom

EORTC Extends Medidata Partnership to Help Power New Phased of Oncology Research

Medidata technology deployed to increase access to and transform the patient experience for cancer trials 11 September 2024 -- London, UK -- Medidata, a Dassault Systèmes brand and leading provider...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 11, 2024

350 Hudson Street New York, NY 10014 USA

AI can detect lung nodules that could lead to lung cancer nearly 3 years before symptoms and actual diagnosis, study finds

Evidence presented at 2024 World Conference on Lung Cancer highlights chest X-ray AI’s potential to detect lung nodules early and expedite patient care 10 September 2024 -- New York, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024

C/O RODl & Partner Legal Limited, 170 Edmund Street, Birmingham, United Kingdom B3 2HB 74909

ERS: Dupixent data reinforce clinically meaningful benefit from pooled analysis of two COPD phase 3 studies

Pooled results from the BOREAS and NOTUS studies show meaningful clinical benefit with 31% reduction in exacerbations along with lung function improvement Data from these two phase 3 studies supported...

Category: Clinical Trials, Drug Delivery, Pharmaceutical
Posted: September 10, 2024

One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Abacus Medicine Pharma Services and Mirum Pharmaceuticals Sign Partnership Agreement for the Commercialization of Livmarli in the Nordics

10 September 2024 -- Copenhagen, Denmark -- Abacus Medicine Pharma Services (‘Abacus’) announces the signing of a partnership agreement with Mirum Pharmaceuticals, Inc. (‘Mirum’) for the commercialization of LIVMARLI® (maralixibat)...

Category: Drug Delivery, Other, Pharmaceutical
Posted: September 10, 2024

Kalvebod Brygge 35 1560 Copenhagen V Denmark

Research Integrity, AI Applications for Drug Discovery Covered in Opening and Closing Plenaries at PharmSci 360Registration for Now Open

Arlington, VA—AAPS is excited to announce the opening and closing plenary speakers for the 2024 PharmSci 360, taking place October 20-23 in Salt Lake City, Utah. PharmSci 360 opens on...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024

PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

Investment to enable progression of pipeline of novel degrader assets through pre-clinical development and support further development of GlueSEEKER platform Led by Parkwalk Advisors alongside existing investors BGF, Dr Jonathan...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 10, 2024

PhoreMost Ltd, Building B580, Room 2011, Babraham Research Campus, Babraham, Cambridge, CB22 3AT, United Kingdom

ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement

Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range of drug discovery applications 04 September 2024 – Dublin, Ireland, and Cheshire, UK – ERS...

Category: BioManufacturing
Posted: September 9, 2024

8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

Epsilogen completes £12.5 million Series B financing expansion

Expansion brings total Series B funds raised to £43.25 million Proceeds to support the delivery of clinical Proof of Concept for MOv18 IgE 9 September 2024 -- London, UK --...

Category: Drug Discovery, Other, Pharmaceutical
Posted: September 9, 2024

Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH

CPHI Milan Announce Pharma Award finalists

Finalists span 14 categories including awards for future leaders, women of the year and ‘at the heart of pharma’ 06 September 2024 – MIlan, Italy – CPHI Milan (8-10 October 2024)...

Category: Pharmaceutical
Posted: September 9, 2024

5 Howick Place, London SW1P 1WG

RYBREVANT▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy Results from an interim analysis featured in late-breaker...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 8, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Braunform is a KLIMAfit Company

Braunform GmbH, based in Bahlingen and Endingen a. K., Germany, has successfully participated in the KLIMAfit program and received an award from the Baden-Württemberg Ministry for the Environment, Climate Protection...

Category: Logistics
Posted: September 6, 2024

Rentschler Biopharma introduces new lentiviral vector manufacturing toolbox for advanced therapies

Expanded service offering client ready at company’s site in Stevenage, UK Offering includes process development and cGMP manufacturing services, as well as complementary in-house analytical and regulatory support for lentiviral...

Category: BioManufacturing, Pharmaceutical Contractors
Posted: September 5, 2024

Erwin-Rentschler-Str. 21 88471 Laupheim Germany

Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation

Castres, France, August 30, 2024 – Pierre Fabre Laboratories announced today that the European Commission (EC) has approved BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult...

Category:
Posted: September 5, 2024

1 Avenue d'Albi, Castres, Occitanie 81100, Tarn, France.